You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 11,413,277

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,413,277

Title:	Non-aqueous liquid nimodipine compositions
Abstract:	Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
Inventor(s):	Thomas; Hugh Greg (Carrollton, GA)
Assignee:	Arbor Pharmaceuticals, LLC (Atlanta, GA)
Application Number:	17/558,924
Patent Claims:	1. A composition comprising nimodipine as the only active ingredient and one or more solvents selected from ethanol, polyethylene glycol, and glycerin, wherein about 5% or less nimodipine degradation is observed over a period of at least six months when exposed to 40.degree. C. and 75% relative humidity, and the concentration of nimodipine in the composition is about 6 mg/mL. 2. The composition of claim 1, further comprising from about 0.01% to about 1.5% nimodipine related compound A. 3. The composition of claim 1, wherein nimodipine is present in an amount from about 10 mg to about 100 mg per dosage unit. 4. The composition of claim 1, wherein nimodipine is present in an amount of about 60 mg per dosage unit. 5. A method of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms comprising enterally administering to a patient in need thereof an effective amount of the composition of claim 1. 6. The method of claim 5, wherein the composition is administered orally, via nasogastric tube or via gastric tube. 7. The method of claim 5, wherein a first unit dose of the composition is administered to the patient within about 100 hours of the subarachnoid hemorrhage. 8. The method of claim 5, wherein the composition is administered about every four hours.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.